3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Endometrial Neoplasms
1
Anus Neoplasms
1
Interventions
Radiotherapy
11
Brachytherapy
8
fludarabine
5
Radiation
5
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
5
Cyclophosphamide
5
aldesleukin
4
Surveys and Questionnaires
4
Magnetic Resonance Spectroscopy
4
Cisplatin
4
fludarabine phosphate
3
durvalumab
3
Vaccines, Synthetic
3
Radiosurgery
3
Papillomavirus Vaccines
3
Paclitaxel
3
Methods
3
Early Intervention, Educational
3
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
3
tremelimumab
2
entinostat
2
aflibercept
2
Vaccines
2
Trastuzumab
2
Topotecan
2
Therapeutics
2
Surgical Procedures, Operative
2
Psychiatric Rehabilitation
2
Platinum
2
Palliative Care
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vaginal Neoplasms
×
alovudine
×
Gynecologic
×
Clear all
NCT01399658
2023-03-14
AMIGO
Dana-Farber Cancer Institute
Phase 2
Completed
93 enrolled
5 charts